Stem Cell Synergy Solution

• Cell culture matrix consisting of recombinant Laminin-511 E8 fragments.
• Sustains long term propagation of wide variety of cell types, especially pluripotent cells.
• Superior adhesion of human PSCs.
• Time-saving coating-free method.
• Superior for single cell cloning e.g. in CRISPR/Cas9 gene editing.

• Reliable and safe cryopreservation media for applications in advanced therapies, such as cell therapy.
  
• Animal component-free and chemically defined, with ingredients already approved for intravenous administration.
• No requirement for washing of the cryopreservation solution upon delivery of the cell therapy product.
• High cell viability post-thaw, and high retention of cell identity.

Small molecules are cell permeable, organic compounds with low molecular weights, that can be used as tools to manipulate cell fates via the targeting of signalling pathways. This makes small molecules extremely useful in regenerative medicine research and cancer research.

Explore our range of small molecules, and advance your life science research today!

• Professor Ryuhei Hayashi and colleagues at Osaka University in Japan have described a protocol using all Stem Cell Synergy products to generate transplantable corneal epithelium from human induced pluripotent stem cells (hiPSCs). This was achieved by isolating differentiated cells from specific concentric zones relating to different lineages of whole eye development, termed the SEAM.
• The researchers used StemFit medium for the pre-culture and maintenance of human iPSCs and the iMatrix-511 Laminin E8 fragments for both hiPSC culture and as a substrate for the growth of cells and tissues of the eye.
• Clinical trials began in 2019, where the first patient with corneal epithelial stem cell deficiency had a hiPSC-generated cornal epithelium transplant, to evalute safety and efficacy.

•  Monocytes and macrophages play a vital role in our innate immune response, with impaired function of these cells being associated with both autoimmune and metabolic disorders. To advance treatments for these diseases, a reliable source of human monocytes is essential.
• At the Boehringer Ingelheim Pharmaceutical company, Dr Di Cui and colleagues have developed a serum-free protocol, using StemFit media and iMatrix-511 E8 fragments, to differentiate hiPSCs into human monocytes - with a 30-fold higher yield compared to the previous protocol.
• The study also highlights the feasibility of producing gene-edited hiPSC-derived macrophages by conducting CRISPR/Cas9 gene editing on hiPSCs and obtaining single KO clones, which can then undergo differentiation.
• Potential application: large scale production of therapeutic macrophages engineered wtih chimeric antigen receptors (CARs) to attack solid cancer tumours (Klichinsky et al. 2020).

A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.
Yamanaka, S. et al. Scientific Reports, 2014, 4, 359

An effective serum- and xeno-free chemically defined freezing procedure for human embryonic and induced pluripotent stem cells
Holm, F. et al. Human reproduction, 2010, 25(5), 1271-1279

Co-ordinated ocular development from human iPS cells and recovery of corneal function
Hayashi, R. et al. Nature, 2016, 531(7594), 376-380

Coordinated generation of multiple ocular-like cell lineages and fabrication of functional corneal epithelial cell sheets from human iPS cells.
Hayashi, R. et al. Nature Protocols, 2017, 12(4), 683-696

Efficient Adhesion Culture of Human Pluripotent Stem Cells Using Laminin Fragments in an Uncoated Manner.
Miyazaki, T. et al. Scientific reports, 2017, 7, 41165

High-Yield Human Induced Pluripotent Stem Cell-Derived Monocytes and Macrophages Are Functionally Comparable With Primary Cells
Cui, D. et al. Frontiers in cell and developmental biology, 2021, 9, 656867-656867

Modelling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. 
Sano, E. et al. iScience, 2021, 24(5), 102428-102428